What is it about?
We evaluated the impact on the available supply of plasma and apheresis platelets from three different policies to mitigate TRALI (Transfusion related acute lung injury).
Featured Image
Why is it important?
Transfusion related acute lung injury (TRALI) is an adverse transfusion event with a mortality rate of 5–25%, and has become the leading cause of transfusion associated death in the USA. Selected policies to mitigate TRALI that can be applyed in Brazil include: to distribute plasma-containing products collected from male-only donors, to defer all female donors from apheresis platelet collection, and to defer only multiparous female donors from apheresis platelet collection.
Perspectives
A deferral policy on multiparous apheresis platelet donors may be acceptable as a temporary measure in the absence of reference centers to screen donors for HLA and HNA antibodies and/or the implementation of other techniques to treat plasma containing products, but may cause more stress on a system that already works at its blood availability limit.
Dr Cesar de Almeida-Neto
Faculty of Medicine, University of São Paulo
Read the Original
This page is a summary of: The impact of policies to restrict the use of plasma containing products and apheresis platelets from female donors to mitigate transfusion related acute lung injury (TRALI) in Brazil, Transfusion and Apheresis Science, February 2013, Elsevier,
DOI: 10.1016/j.transci.2012.07.010.
You can read the full text:
Contributors
The following have contributed to this page
